NEWS
Print Your Certificate
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
Henry Fok
i
King's College London - London / United Kingdom
Medical and Health Sciences / Cardiology
AD Scientific Index ID: 1192066
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Henry Fok's MOST POPULAR ARTICLES
1-)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKM Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...The Lancet 397 (10269), 99-111, 202140772021
2-)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...The Lancet 396 (10249), 467-478, 202022602020
3-)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ...The Lancet 396 (10267), 1979-1993, 202012862020
4-)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...The Lancet 397 (10277), 881-891, 202113892021
5-)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trialKRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...The Lancet 397 (10282), 1351-1362, 20217582021
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept